Allogeneic Transplantation
Multiple Myeloma Trials
COMIRB: 23-0376
(CaMMouflage) A Phase I Multicenter, Open-Label Study of CB011, a CRISPR-Edited Allogenic, Anti-BCMA CAR-T Cell Therapy in Patients with Relapsed or Refractory Multiple Myeloma
PI: Dan Sherbenou
Eligibility: Ages ≥ 18; diagnosed MM and evidence of PD based on IMWG criteria; ECOG of ≤1
COMIRB: 22-0931
A Phase I/II, Open-Label, Multi-Cohort Study to Evaluate the Efficacy and Safety of Cevostamab in Prior B Cell Maturation Antigen-Exposed Patients with Relapsed/Refractory Multiple Myeloma
Principal Investigator: Dan Sherbenou
Eligibility: Ages ≥ 18; diagnosed MM and evidence of PD based on IMWG criteria; ECOG of ≤1
COMIRB: 17-1502
An Open-Label, Multicenter, Phase I Trial Evaluating the Safety and Pharmacokinetics of Escalating Doses of BFCR4350A in Patients with Relapsed or Refractory Multiple Myeloma
PI: Dan Sherbenou
Eligibility: Age ≥ 18 years; relapsed/refractory multiple myeloma; ECOG of 0 or 1
COMIRB: 20-2202
Personalized Selinexor-based Therapy for Relapsed/Refractory Multiple Myeloma
PI: Dan Sherbenou
Eligibility: Age ≥ 18 years; relapsed/refractory multiple myeloma; ECOG of ≤2
Request an Appointment
If you would like to schedule an appointment, please give us a call.
Our intake coordinator will help you navigate the process of becoming a new patient including helping you obtain the necessary referrals, get the necessary medical records transferred, and coordinate care with your existing physicians. We are available to answer your questions about our clinic, your treatment, and participation in ongoing clinical trials.